Editorial: Molecular mechanisms in lethal states of prostate cancer.
作者信息
Kim Daniel M, Lyou Yung, Ellis Leigh, Posadas Edwin, Bhowmick Neil, Gong Jun
机构信息
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Department of Oncology, Providence St. Jude Medical Center, Fullerton, CA, United States.
出版信息
Front Oncol. 2024 Aug 20;14:1475178. doi: 10.3389/fonc.2024.1475178. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Molecular mechanisms in lethal states of prostate cancer.社论：前列腺癌致死状态的分子机制
Front Oncol. 2024 Aug 20;14:1475178. doi: 10.3389/fonc.2024.1475178. eCollection 2024.
2
Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.原发性前列腺癌中预先存在的去势抵抗性前列腺癌细胞样细胞促进对激素治疗的抵抗。
Eur Urol. 2022 May;81(5):446-455. doi: 10.1016/j.eururo.2021.12.039. Epub 2022 Jan 17.
3
PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer.靶向雄激素受体信号的 PROTACs：用于治疗去势抵抗性前列腺癌的潜在治疗剂。
Pharmacol Res. 2024 Jul;205:107234. doi: 10.1016/j.phrs.2024.107234. Epub 2024 May 28.
4
Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.针对去势抵抗性前列腺癌中持续存在的雄激素受体信号传导
Med Oncol. 2016 May;33(5):44. doi: 10.1007/s12032-016-0759-3. Epub 2016 Apr 4.
5
Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.患者来源的激素敏感型前列腺癌异种移植模型揭示生长因子受体结合蛋白 10 作为雄激素受体抑制基因，驱动去势抵抗性前列腺癌的发展。
Eur Urol. 2018 Jun;73(6):949-960. doi: 10.1016/j.eururo.2018.02.019. Epub 2018 Mar 12.
6
Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.激素敏感性前列腺癌和去势抵抗性前列腺癌中雄激素受体变异体7和泛素结合酶2C的转录水平
Prostate. 2017 Jan;77(1):60-71. doi: 10.1002/pros.23248. Epub 2016 Aug 22.
7
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
8
[COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER].[雄激素剥夺疗法及去势抵抗性前列腺癌药物的成本分析]
Nihon Hinyokika Gakkai Zasshi. 2021;112(2):53-57. doi: 10.5980/jpnjurol.112.53.
9
Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.了解转移性去势抵抗性前列腺癌的耐药机制：雄激素受体的作用
Eur Urol Focus. 2016 Dec;2(5):499-505. doi: 10.1016/j.euf.2016.11.013. Epub 2016 Dec 9.
10
Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.达罗他胺的临床开发：一种用于前列腺癌治疗的新型雄激素受体拮抗剂。
Clin Genitourin Cancer. 2018 Oct;16(5):332-340. doi: 10.1016/j.clgc.2018.07.017. Epub 2018 Jul 24.
本文引用的文献
1
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
2
Advances in the treatment of metastatic prostate cancer.转移性前列腺癌治疗的进展。
Trends Cancer. 2023 Oct;9(10):840-854. doi: 10.1016/j.trecan.2023.06.009. Epub 2023 Jul 11.
3
Deregulated microRNAs Involved in Prostate Cancer Aggressiveness and Treatment Resistance Mechanisms.参与前列腺癌侵袭性和治疗抵抗机制的失调微小RNA
Cancers (Basel). 2023 Jun 10;15(12):3140. doi: 10.3390/cancers15123140.
4
Targeting Glutamine Metabolism in Prostate Cancer.靶向前列腺癌中的谷氨酰胺代谢。
Front Biosci (Elite Ed). 2023 Jan 4;15(1):2. doi: 10.31083/j.fbe1501002.
5
Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit.拮抗 CD105 和雄激素受体以靶向基质-上皮相互作用获得临床获益。
Mol Ther. 2023 Jan 4;31(1):78-89. doi: 10.1016/j.ymthe.2022.08.019. Epub 2022 Aug 31.
6
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.靶向前列腺癌中的信号通路：机制与临床试验。
Signal Transduct Target Ther. 2022 Jun 24;7(1):198. doi: 10.1038/s41392-022-01042-7.
7
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.阿比特龙联合泼尼松加至去势治疗和多西他赛用于初治转移性去势敏感性前列腺癌（PEACE-1）：一项采用2×2析因设计的多中心、开放标签、随机3期研究。
Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.
8
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.达罗他胺与转移性去势敏感性前列腺癌的生存
**注**：这是基于你提供的文本进行的翻译，实际翻译可能会因上下文和语言习惯而有所不同。
N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17.
9
Prostate cancer.前列腺癌。
Lancet. 2021 Sep 18;398(10305):1075-1090. doi: 10.1016/S0140-6736(21)00950-8. Epub 2021 Aug 6.
10
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.伊帕替膦联合阿比特龙和泼尼松治疗转移性去势抵抗性前列腺癌（IPATential150）：一项多中心、随机、双盲、III 期临床试验。
Lancet. 2021 Jul 10;398(10295):131-142. doi: 10.1016/S0140-6736(21)00580-8.
Zotero 插件